Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alexion

This article was originally published in The Gray Sheet

Executive Summary

New Haven, Connecticut-based pharmaceutical company forms post-genomics discovery company Arradial, Inc. to commercialize desktop, silicon-based microarray assay technology. The Boston start-up hopes to close a $3 mil. seed round of venture capital financing by year-end. Former Fisher Scientific President and Chief Operating Officer and Alexion co-founder Thomas Vogel will become Arradial's President and CEO. Arradial is "excited to be developing this desktop laboratory personal screening system - the LabPS - to meet the growing needs of the drug discovery industry in the post genomic era," Vogel stated
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT014026

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel